Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial

Analysts had hoped a prior negative result in acute myeloid leukemia would not read through to Syros’s Phase III myelodysplastic syndrome study, but SELECT-MDS-1 nevertheless failed too.